학술논문
Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project.
Document Type
Academic Journal
Author
Lange B; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany. Berit.Lange@helmholtz-hzi.de.; German Center for Infection Research (DZIF), TI BBD, Brunswick, Germany. Berit.Lange@helmholtz-hzi.de.; Jaeger VK; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.; Harries M; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany.; Rücker V; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.; Streeck H; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany.; Blaschke S; Emergency Department, University Medical Center Göttingen, Göttingen, Germany.; Petersmann A; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg, Oldenburg, Germany.; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.; Toepfner N; Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Nauck M; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.; DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine Greifswald, Greifswald, Germany.; Hassenstein MJ; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany.; Dreier M; Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.; von Holt I; Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.; Budde A; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany.; Bartz A; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.; Ortmann J; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany.; Kurosinski MA; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.; Berner R; Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Borsche M; Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.; Brandhorst G; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg, Oldenburg, Germany.; Brinkmann M; Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.; Budde K; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.; Deckena M; MVZ Labor Krone GbR, Bad Salzuflen, Germany.; Engels G; Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.; Fenzlaff M; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.; Härtel C; Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.; Hovardovska O; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany.; Katalinic A; Institute of Social Medicine and Epidemiology, University of Luebeck, Luebeck, Germany.; Kehl K; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany.; Kohls M; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.; Krüger S; Dimap, das Institut Für Markt- Und Politikforschung GmbH, Bonn, Germany.; Lieb W; Institute of Epidemiology, Christian-Albrechts-University of Kiel, Kiel, Germany.; Meyer-Schlinkmann KM; MVZ Labor Krone GbR, Bad Salzuflen, Germany.; Pischon T; Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.; Biobank Technology Platform, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.; Charité-Universitätsmedizin Berlin, Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Rosenkranz D; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg, Oldenburg, Germany.; Rübsamen N; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.; Rupp J; Department of Infectious Diseases and Microbiology, University Hospital Schleswig-Holstein, German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.; Schäfer C; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.; Schattschneider M; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.; Schlegtendal A; University Children's Hospital, Ruhr University Bochum, Bochum, Germany.; Schlinkert S; Dimap, das Institut Für Markt- Und Politikforschung GmbH, Bonn, Germany.; Schmidbauer L; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.; Schulze-Wundling K; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany.; Störk S; Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center (CHFC), and Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.; Tiemann C; MVZ Labor Krone GbR, Bad Salzuflen, Germany.; Völzke H; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.; Winter T; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.; Klein C; Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.; Liese J; Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.; Brinkmann F; University Children's Hospital, Ruhr University Bochum, Bochum, Germany.; Ottensmeyer PF; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany.; Reese JP; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.; Institute for Medical Data Science, University Hospital Würzburg, Würzburg, Germany.; Heuschmann P; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.; Institute for Medical Data Science, University Hospital Würzburg, Würzburg, Germany.; Clinical Trial Center, University Hospital Würzburg, Würzburg, Germany.; Karch A; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany. akarch@uni-muenster.de.
Source
Publisher: Springer Heidelberg Country of Publication: Germany NLM ID: 0365307 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-0973 (Electronic) Linking ISSN: 03008126 NLM ISO Abbreviation: Infection Subsets: MEDLINE
Subject
Language
English
Abstract
Purpose: Despite the need to generate valid and reliable estimates of protection levels against SARS-CoV-2 infection and severe course of COVID-19 for the German population in summer 2022, there was a lack of systematically collected population-based data allowing for the assessment of the protection level in real time.
Methods: In the IMMUNEBRIDGE project, we harmonised data and biosamples for nine population-/hospital-based studies (total number of participants n = 33,637) to provide estimates for protection levels against SARS-CoV-2 infection and severe COVID-19 between June and November 2022. Based on evidence synthesis, we formed a combined endpoint of protection levels based on the number of self-reported infections/vaccinations in combination with nucleocapsid/spike antibody responses ("confirmed exposures"). Four confirmed exposures represented the highest protection level, and no exposure represented the lowest.
Results: Most participants were seropositive against the spike antigen; 37% of the participants ≥ 79 years had less than four confirmed exposures (highest level of protection) and 5% less than three. In the subgroup of participants with comorbidities, 46-56% had less than four confirmed exposures. We found major heterogeneity across federal states, with 4-28% of participants having less than three confirmed exposures.
Conclusion: Using serological analyses, literature synthesis and infection dynamics during the survey period, we observed moderate to high levels of protection against severe COVID-19, whereas the protection against SARS-CoV-2 infection was low across all age groups. We found relevant protection gaps in the oldest age group and amongst individuals with comorbidities, indicating a need for additional protective measures in these groups.
(© 2023. The Author(s).)
Methods: In the IMMUNEBRIDGE project, we harmonised data and biosamples for nine population-/hospital-based studies (total number of participants n = 33,637) to provide estimates for protection levels against SARS-CoV-2 infection and severe COVID-19 between June and November 2022. Based on evidence synthesis, we formed a combined endpoint of protection levels based on the number of self-reported infections/vaccinations in combination with nucleocapsid/spike antibody responses ("confirmed exposures"). Four confirmed exposures represented the highest protection level, and no exposure represented the lowest.
Results: Most participants were seropositive against the spike antigen; 37% of the participants ≥ 79 years had less than four confirmed exposures (highest level of protection) and 5% less than three. In the subgroup of participants with comorbidities, 46-56% had less than four confirmed exposures. We found major heterogeneity across federal states, with 4-28% of participants having less than three confirmed exposures.
Conclusion: Using serological analyses, literature synthesis and infection dynamics during the survey period, we observed moderate to high levels of protection against severe COVID-19, whereas the protection against SARS-CoV-2 infection was low across all age groups. We found relevant protection gaps in the oldest age group and amongst individuals with comorbidities, indicating a need for additional protective measures in these groups.
(© 2023. The Author(s).)